Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dara L Aisner

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literatureBradford J Siegele, Konstantin Shilo, Bo H Chao, et al.
Archives of Pathology & Laboratory Medicine|June 7, 2022
Four-Year Laboratory Performance of the First College of American Pathologists In Silico Next-Generation Sequencing Bioinformatics Proficiency Testing SurveysLarissa V Furtado, Rhona J Souers, Patricia Vasalos, et al.
Melanoma Research|November 6, 2020
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomasBlair N Holman, Robert J Van Gulick, Carol M Amato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersBob T Li, Dara S Ross, Dara L Aisner, et al.
Oncotarget|February 19, 2015
Activation of RAS family members confers resistance to ROS1 targeting drugsMarilisa Cargnelutti, Simona Corso, Margherita Pergolizzi, et al.
JTO Clinical and Research Reports|April 14, 2025
Novel <i>PLEC-EML4-ALK</i> Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case ReportAlessandra Maleddu, Trista K Hinz, Margaret A Black, et al.
The Journal of Molecular Diagnostics : JMD|June 7, 2020
Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular PathologyAnthony N Sireci, Jay L Patel, Loren Joseph, et al.
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on CrizotinibTejas Patil, Derek E Smith, Paul A Bunn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literatureBradford J Siegele, Konstantin Shilo, Bo H Chao, et al.
Archives of Pathology & Laboratory Medicine|June 7, 2022
Four-Year Laboratory Performance of the First College of American Pathologists In Silico Next-Generation Sequencing Bioinformatics Proficiency Testing SurveysLarissa V Furtado, Rhona J Souers, Patricia Vasalos, et al.
Melanoma Research|November 6, 2020
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomasBlair N Holman, Robert J Van Gulick, Carol M Amato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung CancersBob T Li, Dara S Ross, Dara L Aisner, et al.
Oncotarget|February 19, 2015
Activation of RAS family members confers resistance to ROS1 targeting drugsMarilisa Cargnelutti, Simona Corso, Margherita Pergolizzi, et al.
JTO Clinical and Research Reports|April 14, 2025
Novel <i>PLEC-EML4-ALK</i> Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case ReportAlessandra Maleddu, Trista K Hinz, Margaret A Black, et al.
The Journal of Molecular Diagnostics : JMD|June 7, 2020
Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular PathologyAnthony N Sireci, Jay L Patel, Loren Joseph, et al.
Cancer|December 15, 2018
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancerTerry L Ng, Yiwei Liu, Anastasios Dimou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2018
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on CrizotinibTejas Patil, Derek E Smith, Paul A Bunn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation ConsortiumRobin Guo, Lynne D Berry, Dara L Aisner, et al.
Pageof 13